Method for stimulating a host immune system by administering an allogeneic cell material

Abstract

A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and / or radiation conditioning regimens.

Description

[0001]The present application is based on and claims the benefit of U.S. provisional patent application Ser. No. 60 / 470,171, filed May 13, 2003, U.S. provisional application Ser. No. 60 / 545,450, filed Feb. 18, 2004, U.S. provisional application Ser. No. 60 / 547,966, filed Feb. 26, 2004 and U.S. provisional application Ser. No. 60 / 549,032, filed Mar. 1, 2004.FIELD OF INVENTION[0002]This invention relates to the use of allogeneic cell infusions to treat disease. More particularly, the invention relates to an allogeneic cell therapy method enabling the generation of an anti-tumor effect in the absence of graft vs. host (GVH) disease toxicity.BACKGROUND OF THE INVENTION[0003]Allogeneic cell therapy is an important curative therapy for several types of malignancies and viral diseases. Allogeneic cell therapy involves the infusion or transplant of cells to a patient, whereby the infused or transplanted cells are derived from a donor other than the patient. Types of allogeneic donors that h...

AI Technical Summary

Benefits of technology

"The invention is about a method for producing a product that uses allogeneic cells, specifically T-cells, to stimulate the immune system of a patient without causing graft-versus-host disease. The allogeneic T-cells are expanded and differentiated ex-vivo, and are then rejected by the patient's immune system. This method can be used to treat tumors, hematological malignancies, solid tumors, and viral infections. The allogeneic T-cells are chosen without regard to histocompatibility, and maximum histocompatibility mismatch is preferred. The method also involves activating the T-cells by cross-linking anti-CD3 and anti-CD28 mAbs applied to the cell surface, and stimulating the production of Type 1 cytokines and host dendritic and / or macrophage cells. Overall, this invention provides a way to safely and effectively stimulate the immune system of a patient without causing harmful side effects."

Problems solved by technology

This requirement for a matched donor is a major limitation of allogeneic cell therapy protocols.

This myeloablative conditioning results in destruction of the bone marrow leading to the loss of a functioning immune system.

The high risk of transplant related mortality has limited the use of this treatment mostly to otherwise healthy patients with hematological malignancies.

1998), the clinical application of GVT is still severely limited due to the toxicity associated with allogeneic cell infusions.

GVH disease occurs when donor T-cells react against antigens on normal host cells causing target organ damage, which often leads to death.

However, this has proven to be very difficult, as it appears that GVT and GVH are intimately related processes, with the same donor T-cells responsible for both effects.

Attempts to perform allogeneic BMT between strongly HLA-mismatched donor-recipient pairs have been associated with a prohibitively high incidence of severe GVH disease and failure of the allogeneic cell infusions to engraft.

The requirement for an HLA matched donor severely limits the application of allogeneic cell therapy.

Only approximately one of every three patients has an HLA-matched sibling or can find a phenotypically matched unrelated donor, and therefore the majority of patients do not have the option of allogeneic cell therapy.

Furthermore, a large fraction of cancers, including leukemias and lymphomas, afflict older patients who are more prone to the development of GVH disease than are younger persons, and who therefore are not generally considered candidates for allogeneic cell therapy, despite the lack of other curative options.

In addition, the immunosuppressive drugs used for GVH disease prophylaxis also increase the risk of secondary infection and increase the relapse rates for certain types of leukemia.

Images